Syringe Driver Survey Database migration to MedicinesComplete - January 2023

Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.

It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.

Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.

Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/

If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023. 

To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html

To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales

If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.

---

Legislation changes for the availability of parenteral naloxone

28th July 2015

From the 1 October 2015, parenteral naloxone can be supplied for use by drug treatment services for the purpose of saving life in an emergency. This follows changes in the medicines regulations to allow wider access to parenteral naloxone for use in emergencies, with the aim of reducing deaths arising from acute opioid overdose associated with the misuse of strong opioids such as heroin.

Editor's note: This is not to be confused with the management of iatrogenic opioid-induced respiratory depression in those receiving long-term opioids for pain relief. In this situation, the dose of naloxone is significantly lower than that recommended for acute opioid overdose, see Opioid antagonists monograph in the PCF and the recent patient safety alert NHS/PSA/W/2014/016R (see our news item 27 November 2014).

click here to view